Results 31 to 40 of about 1,145 (113)

Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug–drug interactions

CPT: Pharmacometrics &Systems Pharmacology, Volume 13, Issue 4, Page 563-575, April 2024.
Abstract Considerable interest remains across the pharmaceutical industry and regulatory landscape in capabilities to model oral contraceptives (OCs), whether combined (COCs) with ethinyl estradiol (EE) or progestin‐only pill. Acceptance of COC drug–drug interaction (DDI) assessment using physiologically‐based pharmacokinetic (PBPK) is often limited to
Gareth J. Lewis, Deepak Ahire, Kunal S. Taskar   +2 more
wiley   +1 more source

Stop codon readthrough as a treatment option for epidermolysis bullosa—Where we are and where we are going

Experimental Dermatology, Volume 33, Issue 3, March 2024.
Abstract In the context of rare genetic diseases caused by nonsense mutations, the concept of induced stop codon readthrough (SCR) represents an attractive avenue in the ongoing search for improved treatment options. Epidermolysis bullosa (EB)—exemplary for this group of diseases—describes a diverse group of rare, blistering genodermatoses ...
Johanna Zandanell, Michael Wießner, Johann W. Bauer, Roland N. Wagner   +3 more
wiley   +1 more source

Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

Clinical Pharmacology &Therapeutics, Volume 115, Issue 1, Page 71-79, January 2024.
Ticagrelor and rosuvastatin are often used concomitantly after atherothrombotic events. Several cases of rhabdomyolysis during concomitant ticagrelor and rosuvastatin have been reported, suggesting a drug–drug interaction. We showed recently that ticagrelor inhibits breast cancer resistance protein (BCRP) and organic anion transporting polypeptide ...
Minna Lehtisalo, E. Katriina Tarkiainen, Mikko Neuvonen, Mikko Holmberg, Johanna I. Kiiski, Outi Lapatto‐Reiniluoto, Anne M. Filppula, Mika Kurkela, Janne T. Backman, Mikko Niemi   +9 more
wiley   +1 more source

FORMULATION AND OPTIMIZATION OF FLOATING SUSTAINED RELEASE TABLETS OF ATAZANAVIR SULFATE THROUGH BOX-BEHNKEN DESIGN

Asian Journal of Pharmaceutical and Clinical Research
Objective: Atazanavir (ATZ) sulfate is widely prescribed as an antiretroviral drug belonging to BCS class II with low solubility. This research aims to design, formulate, and optimization of floating sustained-release tablets of ATZ through Box-Behnken design (BBD). Method: The formulation parameters were optimized using the BBD. Methocel K100M (A) was
null BALIJEPALLI MURALI KRISHNA, null CHANDRA SEKHAR PATRO, null CH. TARAKA RAMARAO   +2 more
openaire   +1 more source

Abstract Supplement Abstracts from IAS 2025, the 13th IAS Conference on HIV Science, 13 – 17 July, Kigali, Rwanda & Virtual

Journal of the International AIDS Society, Volume 28, Issue S4, July 2025.
wiley   +1 more source

Poster Session 2

Pregnancy, Volume 1, Issue S1, January 2025.
wiley   +1 more source

Potential drug-drug interactions of frequently prescribed medications in long COVID detected by two electronic databases. [PDF]

PLoS One, 2023
Meakleartmongkol T, Tangpanithandee S, Vanavivit N, Jiso A, Pongchaikul P, Kirdlarp S, Khemawoot P, Nathisuwan S.   +7 more
europepmc   +1 more source

New UV Spectrophotometric Method for the Estimation of Atazanavir Sulfate in Bulk and Pharmaceutical Dosage Form

Scholars Academic Journal of Pharmacy, 2020
Soundarya K, Hemant Kumar T, Manjunath SY   +2 more
openaire   +1 more source

Development and Statistical Correlation of Spectrophotometric Methods for Atazanavir Sulfate with Sulphonepthalein Dyes

Asian Journal of Chemistry, 2014
Anindita Behera, Dannana G. Sankar, Swapan K. Moitra, Sudam C . Si   +3 more
openaire   +1 more source

Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial. [PDF]

Immun Inflamm Dis, 2023
Atefi N, Goodarzi A, Riahi T, Khodabandehloo N, Talebi Taher M, Najar Nobari N, Seirafianpour F, Mahdi Z, Baghestani A, Valizadeh R.   +9 more
europepmc   +1 more source